Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jun 29, 2011
ALDERLEY PARK, UK and SOUTH PLAINFIELD, N.J., June 29, 2011 – AstraZeneca and PTC Therapeutics, Inc. (PTC) today announced that they have entered into an exclusive research collaboration and license agreement for the application of PTC's proprietary GEMS™ technology (Gene Expression Modulation by
Additional Formats
Mar 30, 2011
- Jay Barth, M.D. Promoted to Vice President of Clinical Development -
Additional Formats
Mar 02, 2011
- PTC Receives $2.2 Million Payment -
Additional Formats
Feb 01, 2011
- PPMD awards $250,000 grant towards research program-
Additional Formats
Jan 19, 2011
SOUTH PLAINFIELD, NJ – January 19, 2011 – Stuart W. Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc. (PTC), has been elected a Fellow of the American Association for the Advancement of Science (AAAS), the world's largest general scientific society and publisher of the journal Science.
Additional Formats
Dec 21, 2010
- Trial completion is expected in 2011 -
Additional Formats
Dec 01, 2010
SOUTH PLAINFIELD, NJ – December 1, 2010 – Data published in the December issue of the medical journal Muscle and Nerve confirm the utility of six-minute walk distance (6MWD) as a clinically meaningful endpoint in dystrophinopathy, a disease continuum comprising Duchenne and Becker muscular
Additional Formats
Nov 15, 2010
- Data show that ataluren restores the production of functional CFTR protein -
Additional Formats
Oct 26, 2010
- First proof-of-concept clinical study of ataluren in a metabolic disorder -
Additional Formats
Oct 15, 2010
- 29.7 meter average change in 6-minute walk distance compared to placebo at 48 weeks - - Safety results show ataluren was generally well tolerated - - Data to be the basis of interactions with regulatory authorities -

Additional Formats